Trying increasing single and repeated doses of SRK-439 in healthy adults
Official title: A Phase 1 Single- and Multiple-Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SRK-439 in Healthy Adults
Run by Scholar Rock, Inc. · NCT07444294 · Data updated 2026-11-12
This trial tests whether different single and repeated doses of SRK-439 are safe and how the body handles the drug in healthy adults.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 55 Years |
| Sex | All |
| Enrollment | 76 (estimated) |
| Sponsor | Scholar Rock, Inc. Industry-sponsored |
| Drugs / interventions | apitegromab, radiation |
| Locations | 1 site (Cincinnati, Ohio) |
| Status | Recruiting |
| Started | November 21, 2025 |
| Main results expected | December 17, 2026 |
| Study ends | June 9, 2027 |
| Registry record updated | March 2, 2026 |
| Trial ID | NCT07444294 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are healthy men or women aged 18 to 55 with a BMI of 18–35 kg/m2 who are not taking muscle-active drugs and have not previously received SRK-439 or other anti-myostatin therapies.
✕Probably not a fit
People seeking immediate treatment for a medical condition, those currently using anabolic steroids, growth hormones, or other muscle-altering therapies, or those with recent immunosuppressive or certain antibody exposures are unlikely to benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a Phase 1, single- and multiple-ascending dose study in healthy adults that examines safety, tolerability, pharmacokinetics, and pharmacodynamics of SRK-439. Participants will receive either SRK-439 or placebo in sequential dosing cohorts with doses increasing between cohorts. Both single-dose and repeated-dose regimens are included to characterize short-term and repeat-exposure effects. Safety monitoring and blood sampling for PK/PD analyses will be performed throughout the dosing and follow-up periods.
Why it matters
Potential benefit: If successful, this work could speed development of SRK-439 and similar drugs that aim to protect or build muscle, potentially helping people with muscle-wasting conditions.
How similar studies have gone: Other anti-myostatin and related pathway agents have shown some promising biological signals in early trials, but results have varied and this specific compound remains early in clinical testing.
Who can join: the full rules
Show full inclusion / exclusion criteria
Key Inclusion Criteria: 1. Male or female participants, ≥18 to ≤55 years of age, at the time of informed consent 2. BMI of ≥18 kg/m2 to ≤35 kg/m2 (inclusive) at screening Exclusion Criteria: 1. Previous treatment with SRK-439 or apitegromab, or with other anti-myostatin therapies, including ACTR antagonists. 2. History of immunosuppressive, chemotherapeutic, or radiation treatment within 12 months prior to screening. 3. Current or prior use of anabolic steroids, growth hormones, or other substances with known effects on muscle. 4. Use of therapies with potentially significant muscle effects (eg, insulin-like growth factor, systemic beta-agonist, neurotoxins, or muscle relaxants or muscle-enhancing supplements) in any form within 3 months prior to screening or during the study. 5. Any history of exposure to a mAb or Fc domain-bearing recombinant protein within 5 years prior to screening with any prior history of hypersensitivity reactions from exposure 6. Treatment with other investigational drugs or devices in a clinical study or exposure to a biologic therapeutic within 3 months or 5 half-lives, whichever is longer, prior to screening.
Where it's running
-
Medpace CPU
Cincinnati, Ohio, United States Recruiting
Study contacts
- Study coordinator: Scholar Rock, Inc. Clinical Trials Administration
- Email: MedicalInformation@scholarrock.com
- Phone: 857-259-3860
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Do Quercefit® or Ubiqsome™ help with aging and metabolic health in adults 50–75?
This study tests whether Quercefit® or Ubiqsome™ can improve aging markers, blood sugar, and heart health in sedentary adults aged 50–75 compared with a placebo.
-
NVTIA Ergothioneine for Healthy Aging and Skin Health
This study tests whether taking NVTIA Ergothioneine daily for 12 weeks helps healthy adults age more gracefully and keeps skin looking and feeling better compared with a placebo.
-
Miricell supplementation and markers of healthy aging
This trial tests whether taking Miricell once daily for 12 weeks improves cellular health and brain/metabolic indicators in adults aged 40–70 compared with a placebo.
-
Does daily lean beef support brain health in older adults
In healthy adults aged 65 and up, this study tests whether eating lean beef every day for two weeks can influence brain health markers compared with a non-beef, protein-matched option.
-
Adaptive computerized training to boost thinking in healthy seniors and those with mild cognitive impairment
This study tests whether a computer-based training program can improve executive thinking in older adults, including those with mild cognitive impairment, and see if it also helps memory and well-being.
-
SHARP: Personalized Health and Behavior Plan to Lower Biological Age in Older Adults
A 12-month randomized trial tests whether a personalized health and behavior program can lower biological age and improve function in healthy adults over 50.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.